Key clinical point: Disease-modifying antirheumatic drug (DMARD)-naive patients with moderate vs high disease activity at baseline were more likely to achieve Clinical Disease Activity Index for Psoriatic Arthritis (PsA) treatment targets following apremilast therapy.
Major finding: At week 52, remission or low disease activity was achieved by approximately twice the number of patients with moderate vs high disease activity (61.7% vs 28.2%) at baseline, regardless of one or multiple PsA manifestations.
Study details: Findings are from a post hoc analysis of the phase 3 PALACE 4 study including 175 DMARD-naive patients with active PsA who received 30 mg apremilast .
Disclosures: This study received writing support from Amgen. Three authors declared being employees and stockholders of Amgen. The other authors reported ties with several sources, including Amgen.
Source: Mease PJ et al. Baseline disease activity predicts achievement of cDAPSA treatment targets with apremilast: Phase 3 results in DMARD-naive patients with psoriatic arthritis. J Rheumatol. 2022 (Apr 15). Doi: 10.3899/jrheum.210906